QuantiFERON-TB reversion in children and adolescents with tuberculosis

Paula Rodríguez-Molino,Araceli González Sánchez,Antoni Noguera-Julián,Aleix Soler-García,Patricia Martínez Paz,Ana Méndez-Echevarría,Fernando Baquero-Artigao,Miguel González Muñoz,María Jesús Ruíz-Serrano,Manuel Monsonís,Rocío Sánchez León,Jesús Saavedra-Lozano,Begoña Santiago-García,Talía Sainz
DOI: https://doi.org/10.3389/fimmu.2024.1310472
IF: 7.3
2024-03-22
Frontiers in Immunology
Abstract:We analyzed 136 children with tuberculosis disease or infection and a positive QuantiFERON-TB (QFT) assay, followed-up for a median of 21 months (0.4-11years). QFT reversed in 16.9% of cases, with significant decreases in TB1 (-1.72 vs . -0.03 IU/ml, p=0.001) and TB2 (-1.65 vs . -0.43 IU/ml, p=0.005) levels compared to non-reverters. We found a higher QFT reversion rate among children under 5 years (25.0% vs 11.9%, p=0.042), and those with TST induration <15mm (29% vs 13.3%, p=0.055). Our data reveal that, although QFT test remained positive in the majority of children, reversion occurred in 16% of cases in a progressive and stable pattern. Younger age and reduced TST induration were associated with QFT reversion.
immunology
What problem does this paper attempt to address?